*ENG INTA, a deep-tech spin-off from the Scuola Normale Superiore and the National Research Council of Italy, was established in 2020. Our mission is to develop and commercialize the NanoAnalyzer, a portable, rapid, and cost-effective multiplexed biosensing system. This technology is primarily designed for the diagnosis of mild traumatic brain injuries (TBI) through blood analysis. We envision a future where advanced diagnostic tools are accessible to everyone, with a focus on biomedical applications, environmental monitoring, and food safety. Headquartered in Pisa, Italy, we have secured substantial private funding to bring our innovative solutions to the market in 2025 with CE Research Use Only marking.
*ITA INTA, spin-off deep-tech della Scuola Normale Superiore e del Consiglio Nazionale delle Ricerche, è stata fondata nel 2020. La nostra missione è sviluppare e commercializzare il NanoAnalyzer, un sistema biosensoristico portatile, rapido ed economico con capacità di multiplexing. Questa tecnologia è principalmente progettata per la diagnosi di traumi cranici (TBI) attraverso l'analisi del sangue. Immaginiamo un futuro in cui strumenti diagnostici avanzati siano accessibili a tutti, con un focus su applicazioni biomediche, monitoraggio ambientale e sicurezza alimentare. Con sede a Pisa, Italia, abbiamo ottenuto finanziamenti privati significativi per portare le nostre soluzioni innovative sul mercato nel 2025 con marchio CE Research Use Only.
INTA seeks IND-02 partners to optimise and clinically validate NanoAnalyzer for TBI assessment. The portable multiplex platform uses primarily antibody-based immunosensing to measure protein biomarkers, with SAW microfluidics and AI-assisted analysis.
Partner seeks Consortium/Coordinator
Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
INTA seeks TOOL-01 consortia developing AI-based predictive biomarkers for chronic diseases. NanoAnalyzer can provide multiplex protein measurements through affinity biosensing, mainly immunoassays, for integration with longitudinal and multimodal data.
Partner seeks Consortium/Coordinator
Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases